Addressing Significant Unmet Medical Needs
Developing next-generation therapeutics for diseases representing significant unmet medical needs and a burden to society, patients and their families.
Discovering and Developing New Therapies
We are a clinical-stage pharmaceutical company focused on discovering and developing novel therapies for central nervous system, respiratory, and metabolic diseases of huge unmet need. We are committed to developing better, safer, and more effective treatments that can have a real impact on the lives of our patients.
Better Patient Outcomes
Better Safety Profiles
Using chemical genomics driven technology, we are leveraging scientific innovations to discover and develop new medicines with better therapeutic options for patients in need.
Delivering Safe and Efficacious Treatment Options
Our lead drug candidate, brilaroxazine (RP5063), is in clinical development for multiple unmet neuropsychiatric indications including schizophrenia, bipolar disorder, major depressive disorder, behavioral and psychotic symptoms in Alzheimer’s disease, Parkinson’s disease psychosis, and attention deficit hyperactivity disorder (ADHD).
Learn more about our completed and ongoing clinical trials.
Latest News
Reviva to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference
CUPERTINO, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous...
Reviva Announces Positive Full Dataset for 1-Year Phase 3 RECOVER Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia
- Robust broad-spectrum efficacy sustained over 1-year across all symptom domains including negative symptoms - - Generally well-tolerated with low rates of adverse events and discontinuation - - Brilaroxazine improved multiple neuroinflammatory markers reported to...
Reviva to Participate in Upcoming Investor Conferences in May 2025
CUPERTINO, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous...
Corporate Presentation
